Skip to content

Nordic Nanovector adapts clinical development plan for Betalutin® in Follicular Lymphoma

Oslo, Norway, 15 October 2015

  • New plan designed to enhance the chances of Betalutin®,  gaining regulatory approval with a competitive product profile
  • Current cash resources expected to be sufficient until first submission, anticipated 1H 2019

Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that it has taken the decision to revise its clinical development plan for Betalutin®, its lead product candidate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma.

A conference call to discuss the revised development plan will take place today at 9.30 a.m. CET / 8.30 a.m. BST – details below.

Luigi Costa, CEO of Nordic Nanovector, said: “We believe that our decision to revise the clinical development plan for Betalutin® makes good strategic sense. In light of newly available data and experts’ advice with regard to pre-dosing, we have concluded that we now have a new opportunity to determine the best regimen to take into the pivotal Phase 2 PARADIGME trial. We are confident that by establishing the most appropriate regimen through an expanded Phase 1/2 study, rather than as part of PARADIGME, we will greatly improve the chances of successfully gaining regulatory approval for Betalutin® with a product profile that would make it a competitive new treatment for follicular lymphoma. I would like to thank all our advisors for their valuable input to this decision.”

The revised clinical development plan sees the previous dose-finding element of the pivotal PARADIGME trial being expanded and integrated into the Phase 1/2 (Lymrit 37-01) trial that is currently underway. Previously, the dose-finding element was to be conducted in parallel as a ‘run-in’ phase to PARADIGME to potentially accelerate the time to approval. PARADIGME is now being planned as a single arm efficacy and safety trial.

The revised Phase 1/2 trial is projected to read out around the end of Q1 2017 and will allow the selection of the optimal dosing regimen to be used for the amended PARADIGME trial, which is now expected to start in 1H 2017. As a result, the first regulatory submission for Betalutin® is expected in the 1H 2019.

Based on the current plan, the Company expects that cash resources will be sufficient to reach the first regulatory submission despite the extended timelines. This is due to the overall reduction in patient numbers required for the PARADIGME study in the revised plan.

Conference call details

A conference call to discuss the revised development plan will take place today at 9.30 a.m. CET / 8.30 a.m. BST.

Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below:

Local – Norway +47 2350 0486
Local – UK +44 (0)20 3427 1912
Local – USA and International ++1 646 254 3366

Confirmation Code: 4608153

The presentation for the conference call will be publicly available at in the section; Investor relations/Reports and Presentation/Presentation/2015.


For further information, please contact:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Tel: +47 22 18 33 01
Cell: +47 91 51 95 76

International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson) /
Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at


Source: Nordic Nanovector